GNI Japan
VC Fund
Tokyo, Japan
GNI Japan is a VC fund in Tokyo focused on Biotechnology and Pharmaceutical. GNI is a Japanese subsidiary of the US corporation Gene Networks, Inc.(2008 liquidation) and started with basic research on gene analysis by a small team of young scientists. Later, it was listed on the Tokyo Stock Exchange Mothers in 2007 and launched in 2014 as a full-fledged pharmaceutical company by launching a new drug. The Group has businessbases in China and Japan, two of the world's largest economies, and has its own pharmaceutical factory in China, thereby conducting integrated business activities from new drug discovery and clinical development to manufacturing and sales. This is extremely rare in the biotech industry.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries GNI Japan invests in
Stages GNI Japan invests in
Countries GNI Japan invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ying Luo
|
|||
Investment Focus
Industry
- Biotechnology 1 (50%)
- Pharmaceutical 1 (50%)
Stage
- Series C 1 (50%)
- Corporate Round 1 (50%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Ying Luo
President and CEO
|
President and CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cullgen
|
Cullgen is a drug discovery service intended to create new drugs for the treatment of diseases that currently lack effective therapies. The company's services use protein degradation technology that focuses on the selective degradation of disease-causing proteins, a novel treatment for cancer, inflammatory and autoimmune diseases, includingtargets previously considered undruggable, enabling scientists with new means to develop novel therapeutic approaches for various diseases. | $35M / Series C / May 08, 2023 | |
|
Cullgen
|
Cullgen is a drug discovery service intended to create new drugs for the treatment of diseases that currently lack effective therapies. The company's services use protein degradation technology that focuses on the selective degradation of disease-causing proteins, a novel treatment for cancer, inflammatory and autoimmune diseases, includingtargets previously considered undruggable, enabling scientists with new means to develop novel therapeutic approaches for various diseases. | $5M / Corporate Round / May 08, 2023 |
Co-Investors
Sincere Capital
1 deal together
Voyagers Capital
1 deal together
Wuxi Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does GNI Japan invest in?
GNI Japan invests primarily in Biotechnology and Pharmaceutical startups, most often at Series C and Corporate Round stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact GNI Japan?
Public channels for GNI Japan include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at GNI Japan?
The team at GNI Japan includes Ying Luo (President and CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
